Our Blog
Our thoughts on the topics we care about.
ProCESS Trial Results Released Today in NEJM
The long-awaited results of the Protocolized Care for Early Septic Shock (ProCESS) multicenter, randomized clinical trial were released today in the March 2014 issue of the New England Journal of Medicine. ProCESS compared mortality and other outcomes in 1341 patients...
Two days to IMPRESS!!
We want to remind participants in the IMPRESS study that there are now fewer than 2 DAYS left until its start. IMPRESS is an observational study designed to assess the incidence and clinical patterns of septic syndromes on a single day, November 7th, in ICUs and...
Help fight sepsis – Register your facility in the IMPRESS study today!
IMPRESS (International Multicentre PREvalence Study on Sepsis) is an observational study on sepsis and septic shock sponsored by the European Society of Intensive Care (ESICM) and the Society of Critical Care Medicine (SCCM). IMPRESS will analyze de-identified patient...
September 13th is World Sepsis Day!
September 13th is World Sepsis Day, a day dedicated to increasing awareness of sepsis and its devastating consequences among the public and healthcare professionals. Please visit the World Sepsis Day and Global Sepsis Alliance websites to find out more about this...
Eritoran, a Gram-negative bacterial endotoxin blocker, fails Phase 3 clinical trial
Eritoran, a promising first-in-class agent for combating Gram-negative sepsis, failed its Phase 3 clinical trial, according to the results of the ACCESS trial published in the March 20th issue of JAMA. Eritoran is synthetic lipid A antagonist that blocks...